Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial

Autor: Edouard Louis, Matthieu Resche-Rigon, David Laharie, Jack Satsangi, Nik Ding, Britta Siegmund, Geert D'Haens, Laurence Picon, Peter Bossuyt, Lucine Vuitton, Peter Irving, Stephanie Viennot, Christopher A Lamb, Richard Pollok, Filip Baert, Maria Nachury, Mathurin Fumery, Cyrielle Gilletta, Sven Almer, Shomron Ben-Horin, Yoram Bouhnik, Jean-Frederic Colombel, Erik Hertervig, Jane Andrews, Miles Sparrow, Rupert Leong, Susan Connor, Graham Radforth-Smith, Peter De Cruz, Jan Preiss, Andrea Stallmach, Thomas Liceni, Olaf Grip, Jonas Halfvarson, Dharmaraj Durai, Fraser Cummings, Christian Seilinger, Miles Parkes, James Lindsay, Guy Lambrecht, Philippe Van Hootegem, Jean-François Rahier, Marie Dewitte, Xavier Hebuterne, Elise Chanteloup, Romain Altwegg, Stephane Nancey, Guillaume Bouguen, Guillaume Pineton de Chambrun, Floriant Poullenot, Xavier Roblin

Publikováno v: The Lancet Gastroenterology & Hepatology
The Lancet Gastroenterology & Hepatology, 2023, ⟨10.1016/S2468-1253(22)00385-5⟩
The lancet. Gastroenterology & hepatology, Vol. 8, no.3, p. 215-227 (2023)
The Lancet Gastroenterology and Hepatology, 8(3), 215-227. Elsevier Limited

Background: The combination of infliximab and immunosuppressant therapy is a standard management strategy for patients with Crohn's disease. Concerns regarding the implications of long-term combination therapy provided the rationale for a formal clin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d87bfcab1386efda4aa7b7a717c3771
https://u-picardie.hal.science/hal-03947192